EndoChoice Stock Price, News & Analysis (NYSE:GI)

$8.00 0.00 (0.00 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$8.00
Today's Range$7.95 - $8.00
52-Week Range$3.64 - $9.47
Volume14,000 shs
Average Volume131,115 shs
Market Capitalization$208.73 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About EndoChoice (NYSE:GI)

EndoChoice logoEndoChoice Holdings, Inc. is a medical device company. The Company is focused on designing and commercializing a platform of products and services for gastrointestinal (GI) caregivers. The Company offers a range of products and services that span single-use devices and infection control products, pathology and imaging systems. The Company's products are used in colonoscopy and procedures of the upper GI tract, including esophagogastroduodenoscopy (EGD). The Company's imaging products include Fuse system, EndoCart, and Endoscope repair and maintenance. The Company's single-use therapeutic devices include Neptune injection needle, Boa polypectomy snare, Rescue retrieval devices, Blox bite block, TrapEase polyp traps, Hydra irrigation system, EndoGlide+, Compliance EndoKit, SafeStart, EndoKit, CinchPad and GI pathology. The Company serves over 2,500 GI departments that perform endoscopic procedures.

Receive GI News and Ratings via Email

Sign-up to receive the latest news and ratings for GI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Imaging Systems
Sub-IndustryN/A
SectorHealthcare
SymbolNYSE:GI
CUSIPN/A
PhoneN/A

Debt

Debt-to-Equity Ratio0.93%
Current Ratio3.95%
Quick Ratio3.09%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($2.88)
Net IncomeN/A
Net Margins-90.67%
Return on Equity-130.29%
Return on Assets-60.59%

Miscellaneous

Employees501
Outstanding Shares25,390,000

EndoChoice (NYSE:GI) Frequently Asked Questions

What is EndoChoice's stock symbol?

EndoChoice trades on the New York Stock Exchange (NYSE) under the ticker symbol "GI."

How were EndoChoice's earnings last quarter?

EndoChoice Holdings Inc (NYSE:GI) posted its earnings results on Wednesday, May, 4th. The medical equipment provider reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by $0.13. The medical equipment provider earned $18.46 million during the quarter, compared to the consensus estimate of $18.34 million. EndoChoice had a negative net margin of 90.67% and a negative return on equity of 130.29%. The business's quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.00) earnings per share. View EndoChoice's Earnings History.

Who are some of EndoChoice's key competitors?

When did EndoChoice IPO?

(GI) raised $101 million in an IPO on Friday, June 5th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, BofA Merrill Lynch, William Blair and Stifel acted as the underwriters for the IPO.

How do I buy EndoChoice stock?

Shares of EndoChoice can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is EndoChoice's stock price today?

One share of EndoChoice stock can currently be purchased for approximately $8.00.

How big of a company is EndoChoice?

EndoChoice has a market capitalization of $208.73 million. EndoChoice employs 501 workers across the globe.


MarketBeat Community Rating for EndoChoice (GI)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  141
MarketBeat's community ratings are surveys of what our community members think about EndoChoice and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

EndoChoice (NYSE:GI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.332.002.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$7.00$8.50$8.50
Price Target Upside: 12.06% downside12.06% downside6.78% upside6.78% upside

EndoChoice (NYSE:GI) Consensus Price Target History

Price Target History for EndoChoice (NYSE:GI)

EndoChoice (NYSE:GI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/30/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
8/4/2016Stifel NicolausLower Price TargetBuy$10.00 -> $7.00N/AView Rating Details
8/4/2016J P Morgan Chase & CoDowngradeOverweight -> NeutralN/AView Rating Details
3/24/2016Bank of AmericaDowngradeNeutral -> Underperform$10.00N/AView Rating Details
(Data available from 12/15/2015 forward)

Earnings

EndoChoice (NYSE:GI) Earnings History and Estimates Chart

Earnings by Quarter for EndoChoice (NYSE:GI)

EndoChoice (NYSE GI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2016Q116($0.55)($0.68)$18.34 million$18.46 millionViewN/AView Earnings Details
3/3/2016Q415($0.58)($0.53)$19.05 million$18.50 millionViewN/AView Earnings Details
11/5/2015Q315($0.54)($0.47)$18.42 million$18.40 millionViewN/AView Earnings Details
8/6/2015Q215($0.85)($0.60)$17.59 million$18.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

EndoChoice (NYSE:GI) Earnings Estimates

2017 EPS Consensus Estimate: ($2.00)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.57)($0.57)($0.57)
Q2 20171($0.55)($0.55)($0.55)
Q3 20171($0.48)($0.48)($0.48)
Q4 20171($0.40)($0.40)($0.40)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for EndoChoice (NYSE:GI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

EndoChoice (NYSE GI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 31.50%
Institutional Ownership Percentage: 37.32%
Insider Trades by Quarter for EndoChoice (NYSE:GI)
Insider Trades by Quarter for EndoChoice (NYSE:GI)

EndoChoice (NYSE GI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/30/2017Craig WalkerDirectorSell38,000$0.01$380.00
7/18/2017Craig WalkerDirectorSell60,000$0.02$1,200.00
7/14/2017Craig WalkerDirectorSell250,000$0.02$5,000.00
7/11/2017Craig WalkerDirectorSell3,000$0.02$60.00
3/16/2016Mark GilreathCEOBuy20,000$5.06$101,200.00View SEC Filing  
3/15/2016Mark GilreathCEOBuy5,018$5.02$25,190.36View SEC Filing  
3/11/2016David L KaufmanDirectorBuy89,450$4.81$430,254.50View SEC Filing  
3/10/2016David N GillCFOBuy2,000$4.70$9,400.00View SEC Filing  
3/10/2016William R EnquistDirectorBuy10,000$4.74$47,400.00View SEC Filing  
3/8/2016J Scott CarterDirectorBuy21,600$4.72$101,952.00View SEC Filing  
3/7/2016David N GillCFOBuy5,000$4.77$23,850.00View SEC Filing  
11/17/2015Craig WalkerDirectorBuy14,000$0.06$770.00
11/16/2015Craig WalkerDirectorBuy11,000$0.06$605.00
(Data available from 1/1/2013 forward)

Headlines

EndoChoice (NYSE GI) News Headlines

Source:

SEC Filings

EndoChoice (NYSE:GI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

EndoChoice (NYSE:GI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

EndoChoice (NYSE GI) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.